Potential role of Limosilactobacillus fermentum as a probiotic with anti-diabetic properties: A review.
- 2022-09-01
- World journal of diabetes 13(9)
- Diego Cabral Lacerda
- Paulo César Trindade da Costa
- Paula Brielle Pontes
- Lucas Alves Carneiro Dos Santos
- José Patrocínio Ribeiro Cruz Neto
- Cristiane Cosmo Silva Luis
- Vanessa Polyana de Sousa Brito
- José Luiz de Brito Alves
- PubMed: 36188141
- DOI: 10.4239/wjd.v13.i9.717
Study Design
- Type
- Review
Oxidative stress, inflammation, and gut microbiota impairments have been implicated in the development and maintenance of diabetes mellitus. Strategies capable of recovering the community of commensal gut microbiota and controlling diabetes mellitus have increased in recent years. Some lactobacilli strains have an antioxidant and anti-inflammatory system capable of protecting against oxidative stress, inflammation, and diabetes mellitus. Experimental studies and some clinical trials have demonstrated that Limosilactobacillus fermentum strains can beneficially modulate the host antioxidant and anti-inflammatory system, resulting in the amelioration of glucose homeostasis in diabetic conditions. This review presents and discusses the currently available studies on the identification of Limosilactobacillus fermentum strains with anti-diabetic properties, their sources, range of dosage, and the intervention time in experiments with animals and clinical trials. This review strives to serve as a relevant and well-cataloged reference of Limosilactobacillus fermentum strains capable of inducing anti-diabetic effects and promoting health benefits.